Navigation Links
HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
Date:4/25/2012

FRAMINGHAM, Mass. and SYDNEY, April 25, 2012 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN) today announced that NASDAQ has halted trading of the Company's common stock.  The U.S. Food and Drug Administration's (FDA) Circulatory System Devices Advisory Committee meets today to review HeartWare's Premarket Approval (PMA) application for the HeartWare® Ventricular Assist System as a bridge to heart transplantation for patients with end-stage heart failure.

HeartWare's PMA submission encompasses data from HeartWare's pivotal ADVANCE clinical trial, an FDA approved Investigational Device Exemption study designed to evaluate the HVAD System as a bridge to heart transplantation for patients with end-stage heart failure.  Under ADVANCE, 140 patients at 30 hospitals in the U.S. received the HeartWare investigational device between August 2008 and February 2010.  HeartWare submitted the PMA in December 2010. 

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  The HeartWare System has received CE Marking in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: destination therapy and bridge-to-transplant under a continued access protocol.  For additional information, please visit the Company's website at www.heartware.com.

HeartWare International, In
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
3. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
4. HeartWare International Reports Third Quarter Revenues of $7.5 Million
5. HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
6. HeartWare to Present at the UBS 2010 Global Life Sciences Conference
7. HeartWare to Present at Lazard Capital Markets Circulatory Assist Device Day
8. HeartWare to Report Financial Results for Third Quarter of 2010
9. HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009
10. HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
11. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015 ... services market is receiving a huge boost from ... population, higher prevalence of non-communicable diseases, and the ... of the primary healthcare services in the country ... by government polyclinics. In response to the substantial ...
(Date:3/30/2015)... 30, 2015 China Nepstar Chain Drugstore ... a leading retail drugstore chain in China based ... announced its unaudited financial results for the fourth ... Financial HighlightsFor the quarter ended December 31, 2014: ... compared to the fourth quarter of 2013 ...
(Date:3/29/2015)... , March 29, 2015  Three-month paliperidone ... to relapse compared to placebo in patients with ... study published this week in the ... . Results of the study ... Drug Application (NDA) filing for three-month paliperidone palmitate ...
Breaking Medicine Technology:Singapore's Vibrant Healthcare Industry an Attractive Market for Advanced Diagnostic Imaging Services, says Frost & Sullivan 2Singapore's Vibrant Healthcare Industry an Attractive Market for Advanced Diagnostic Imaging Services, says Frost & Sullivan 3Singapore's Vibrant Healthcare Industry an Attractive Market for Advanced Diagnostic Imaging Services, says Frost & Sullivan 4China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 11China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 12China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 13China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 14China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 15New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12
... , SAN DIEGO, Dec. 21 ... their highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, ... The first trial in human subjects, NBI-98854-0801, was a ... in Canada under an approved Clinical Trial Application (CTA) ...
... , CARLSBAD, Calif., Dec. 21 Isis Pharmaceuticals, Inc. ... a $10 million payment from OncoGenex Pharmaceuticals, Inc. (Nasdaq: ... OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 ... that has completed a successful Phase 2 program in patients ...
Cached Medicine Technology:Neurocrine Advances VMAT2 Inhibitor Program 2Neurocrine Advances VMAT2 Inhibitor Program 3Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 2Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 3
(Date:3/30/2015)... March 30, 2015 Poo puts a whole ... could be better than Paleo, or better than the latest ... - just released on the app store! , With ... there is a whole other half to that story. Poo ... Poo, users do the dirty work, and then they can ...
(Date:3/30/2015)... Phoenix Arizona (PRWEB) March 30, 2015 ... risk and compliance (GRC) in the global business community, ... (ITAM) ups the ante by managing big data ... capabilities coupled with the already powerful analytic and logic ... , Michael Peters, CEO of Lazarus Alliance said “The ...
(Date:3/30/2015)... Kansas City, Mo. (PRWEB) March 30, 2015 ... BHMEDS App, a mobile library of medications used ... app—available free for iPhone, iPad and Android—is a ... has published annually since 1999. The useful resource ... medications, including purpose, dosage and frequency, side effects, ...
(Date:3/30/2015)... A new recruitment site has been launched to ... career move. , Millions of new jobs are forecast ... skills in the booming data and analytics sectors.* The ... aggregator, pulling in opportunities from both employers and recruitment ... help candidates find suitable big data and analytics jobs ...
(Date:3/30/2015)... CA (PRWEB) March 30, 2015 Cutting-edge ... for Health 2015 Conference because of the opportunities to ... This year’s conference will highlight parents of recovered children, ... parent, Mary Romaniec, will debut her book Victory over ... Whole Family. Free copies of Victory over Autism will ...
Breaking Medicine News(10 mins):Health News:Building on Success: Next Generation of Cyber Crime Prevention Unveiled! 2Health News:Popular Publication on Behavioral Health Medications Now An App 2Health News:New Global Job Site Launched for Big Data and Analytics Job Seekers 2Health News:AutismOne and Focus for Health Highlight Victory over Autism at Major Chicago Conference Following Autism Awareness Month 2Health News:AutismOne and Focus for Health Highlight Victory over Autism at Major Chicago Conference Following Autism Awareness Month 3
... CHAPEL HILL, N.C., April 18 Sales leaders ... services offered by,Best Practices, LLC and in particular ... the Best Practice Database., (http://www.BestPracticeDatabase.com ) Although documents ... many sales leaders have come to find,outstanding value ...
... WASHINGTON, April 18 The following is being,issued ... and Coalition of Full Service Community Hospitals:, ... and the,conflict of interest it creates between a ... fact, over the last year, the House of,Representatives ...
... LeMaitre,Vascular, Inc. (Nasdaq: LMAT ) announced today ... on April 30, 2008, after the close of the,market. ... be hosted,the same day at 5:00 PM ET. The ... participants may listen to the live webcast at, http://www.lemaitre.com/investor, ...
... much as drug treatments , , FRIDAY, April 18 (HealthDay ... in patients with terminal cancer, according to Japanese researchers ... a total of 517 patients with incurable cancer and ... for these patients was supportive expressive group therapy, in ...
... Masimo CEO and CFO to begin after markets ... close at 2:00 p.m. PT (5:00 p.m. ET), ... the inventor of Pulse CO-Oximetry and,Measure-Through-Motion-and-Low-Perfusion pulse oximetry, today announced it,will ... after the market closes on Tuesday, April 29, 2008., A ...
... Benefit Sharp Rehabilitation Services -, SAN DIEGO, ... will hold its second annual charity event, a ... in Point Loma on June 20th and,21st. More ... throughout California are,expected to participate. This year, representatives ...
Cached Medicine News:Health News:Sales Executives Finding Value in Best Practice Database 2Health News:Statement: Congress Should Include the Physician Self-Referral Provision in the Farm Bill for Patients and Communities 2Health News:Talk Therapy Proves Effective for Terminal Cancer Patients 2Health News:Masimo to Report First Quarter 2008 Financial Results on April 29, 2008 2
... is especially designed for the atraumatic removal ... sleek design of this probe minimizes the ... Due to its 24K gold plating, the ... foreign body incarceration. The magnetic probe is ...
... flexible continuous monitoring, the M3 and M4 ... and neonatal patient care. M Series monitors ... includes a basic set of non-invasive parameters ... Optional Multi-Measurement Server extensions offer Mainstream or ...
... the patients side and in transit., ... measurements in a compact package to match ... care, lower acuity environments, and patient transfer., ... patient monitoring, the IntelliVue MP20 Junior has ...
... High-performance monitoring for flexible care settings., ... monitors combine portability and measurement flexibility ... needs of intermediate care environmentsat the ... strong heritage in patient monitoring, IntelliVue ...
Medicine Products: